HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

James E Galvin Selected Research

luprolide acetate gel depot

1/2021Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


James E Galvin Research Topics

Disease

21Dementia (Dementias)
03/2021 - 11/2005
20Alzheimer Disease (Alzheimer's Disease)
09/2021 - 07/2006
8Parkinson Disease (Parkinson's Disease)
01/2021 - 02/2006
8Cognitive Dysfunction
01/2021 - 07/2006
4Neurodegenerative Diseases (Neurodegenerative Disease)
01/2011 - 06/2004
2Pain (Aches)
01/2021 - 01/2020
2Lewy Body Disease (Lewy Body Dementia)
01/2021 - 01/2011
2Disease Progression
01/2016 - 05/2012
2Hallucinations (Hallucination)
05/2013 - 11/2007
2Amyloid Plaque
01/2011 - 12/2006
1COVID-19
01/2021
1Endometriosis
01/2021
1Prostatic Neoplasms (Prostate Cancer)
01/2021
1Hypertension (High Blood Pressure)
01/2020
1Sarcopenia
01/2020
1Frailty
01/2020
1Atherosclerosis
11/2019
1Delirium
01/2015
1Pathologic Processes
05/2012
1Amyloid angiopathy
01/2011
1Creutzfeldt-Jakob Syndrome (Creutzfeldt-Jakob Disease)
01/2011
1Frontotemporal Dementia (Semantic Dementia)
01/2011
1Prodromal Symptoms
01/2011
1Inflammation (Inflammations)
02/2010
1Stroke (Strokes)
02/2010
1Huntington Disease (Huntington's Disease)
02/2010
1Neuroinflammatory Diseases
11/2007
1Neurobehavioral Manifestations
11/2007
1Miyoshi myopathy
12/2006
1Muscular Diseases (Myopathy)
12/2006

Drug/Important Bio-Agent (IBA)

9Biomarkers (Surrogate Marker)IBA
01/2021 - 07/2006
5Cholinesterase Inhibitors (Anticholinesterases)IBA
10/2020 - 11/2005
5Proteins (Proteins, Gene)FDA Link
01/2011 - 06/2004
4Amyloid (Amyloid Fibrils)IBA
01/2011 - 11/2007
4alpha-SynucleinIBA
04/2008 - 02/2006
3ApolipoproteinsIBA
09/2021 - 07/2013
3Apolipoproteins E (ApoE)IBA
09/2021 - 07/2013
3Amyloid beta-PeptidesIBA
01/2020 - 04/2008
3Donepezil (Aricept)FDA LinkGeneric
01/2010 - 11/2005
2Antipsychotic Agents (Antipsychotics)IBA
01/2020 - 11/2007
2Rivastigmine (Exelon)FDA LinkGeneric
01/2015 - 01/2014
2Dopamine (Intropin)FDA LinkGeneric
02/2008 - 08/2006
1Hormones (Hormone)IBA
01/2021
1luprolide acetate gel depotFDA Link
01/2021
1Cholinesterases (Cholinesterase)IBA
01/2021
1Pharmaceutical PreparationsIBA
01/2021
1GoldIBA
01/2021
1GonadotropinsIBA
01/2021
1Indicators and Reagents (Reagents)IBA
01/2021
1Leuprolide (Lupron)FDA LinkGeneric
01/2021
1Retinaldehyde (Retinal)IBA
01/2021
1Analgesics (Analgesic Drugs)IBA
01/2020
1Hemoglobins (Hemoglobin)IBA
01/2020
1A-factor (Streptomyces)IBA
01/2016
1Prednisolone (Predate)FDA LinkGeneric
07/2013
1SilverIBA
11/2012
1Triglycerides (Triacylglycerol)IBA
06/2012
16-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA
01/2012
1Cholinergic Agents (Cholinergics)IBA
10/2011
1SynucleinsIBA
01/2011
1Prion ProteinsIBA
01/2011
1Docosahexaenoic AcidsIBA
11/2010
12- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA
11/2010
1Amyloid Precursor Protein Secretases (beta-Secretase)IBA
08/2008
1N2- ((2S)- 2- (3,5- difluorophenyl)- 2- hydroxyethanoyl)- N1- ((7S)- 5- methyl- 6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- L- alaninamideIBA
08/2008
1CurcuminIBA
04/2008
1Galantamine (Galanthamine)FDA LinkGeneric
01/2008
1DysferlinIBA
12/2006
1Messenger RNA (mRNA)IBA
06/2004
1Protein AggregatesIBA
06/2004

Therapy/Procedure

7Activities of Daily Living (ADL)
01/2020 - 08/2008
4Therapeutics
01/2021 - 11/2005
2Institutionalization (Institutionalized Persons)
03/2021 - 12/2006
2Drug Therapy (Chemotherapy)
06/2012 - 05/2012
1Secondary Prevention
01/2021
1Pain Management
01/2021
1Long-Term Care
01/2021
1Patient Readmission
01/2015
1Length of Stay
10/2010
1Immunotherapy
11/2007